Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 6, 2016, Pages 1672-1680

  Gutiérrez Gutiérrez, Belén ^a   Bonomo, Robert A ^b,c   Carmeli, Yehuda ^d   Paterson, D L ^ah   Almirante, Benito ^f   Martínez Martínez, Luis ^g   Oliver, Antonio ^h   Calbo, Esther ⁱ   Peña, Carmen ^f   Akova, Murat ^j   Pitout, Johann ^k   Origüen, Julia ^l   Pintado, Vicente ^m   García Vázquez, Elisa ⁿ   Gasch, Oriol ^o   Hamprecht, Axel ^p   Prim, Nuria ^q   Tumbarello, Mario ^r   Bou, German ^s   Viale, Pierluigi ^t   Tacconelli, Evelina ^u   Almela, Manel ^v   Pérez, Federico ^b   Giamarellou, Helen ^w   Cisneros, José Miguel ^a   Schwaber, Mitchell J ^d   Venditti, Mario ^x   Lowman, Warren ^y   Bermejo, Joaquín ^z   Hsueh, Po Ren ^aa   Mora Rillo, Marta ^ab   Gracia Ahulfinger, Irene ^ac   Pascual, Alvaro ^a,ad   Rodríguez Baño, Jesús ^a,ad   Karaiskos, I ^w   Trecarichi, E M ^r   Losito, A R ^r   Hernandez A ⁿ   Gomez J ⁿ   Navarro, F ^q   Mirelis, B ^q   Larrosa, N ^f   Puig, M ^f   Rucci, V ^z   Bartoletti, M ^t   Giannella, M ^t   Riemenschneider, F ^u   Badia, C ⁱ   Xercavins, M ⁱ   Galvez J ^ae   de Cueto, M ^ae   Salamanca, E ^ae   Falcone, M ^af   Russo, A ^af   Daikos, G ^ag   Roilides, E ^ai   Iosifidis, E ^ai   Doi, Y ^aj   Tuon, F F ^ak   San Juan, R ^l   Fernandez Ruiz M ^l   Molina, J ^al   Gonzalez V ^al   Ruiz de Gopegui, E ^h   Marinescu, C I ^h   Farinas M C ^am   Cano, M E ^am   Gozalo, M ^am   Pano Pardo J R ^an   Navarro San Francisco, C ^an   Gomez Zorrilla S ^f   Tubau, F ^f   Pournaras, S ^ao   Tsakris, A ^ao   Zarkotou, O ^ao   Azap, O K ^ap   Souli, M ^aq   Antoniadou, A ^aq   Poulakou, G ^aq   Virmani, D ^ar   Machuca, I ^as   Perez Nadales E ^as   Torre Cisneros, J ^as   Helvaci, O ^j   Sahin, A O ^j   Canton R ^m   Ruiz, P ^m   Fontanals, D ^at   Jove E ^at   more..

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MINISTRY OF HEALTH   (Israel)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁱ HOSPITAL MÚTUA DE TERRASSA   (Spain)

^j HACETTEPE UNIVERSITY   (Turkey)

^k UNIVERSITY OF CALGARY   (Canada)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^m HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^o Hospital Universitari Parc Taulí   (Spain)

^p UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^q HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^r CATHOLIC UNIVERSITY   (Italy)

^s HOSPITAL JUAN CANALEJO   (Spain)

^t UNIVERSITY OF BOLOGNA   (Italy)

^u UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^v HOSPITAL CLÍNIC   (Spain)

^w IASO GENERAL HOSPITAL   (Greece)

^x SAPIENZA UNIVERSITY OF ROME   (Italy)

^y University of the Witwatersrand   (South Africa)

^z HOSPITAL ESPAÑOL   (Argentina)

^aa NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^ab HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^ac UNIVERSITY OF CÓRDOBA   (Spain)

^ad UNIVERSITY OF SEVILLE   (Spain)

^ae Hosp Univ V Macarena   (Spain)

^af Policlinico Umberto I   (Italy)

^ag LAIKO GENERAL HOSPITAL   (Greece)

^ah ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^ai Aristotle University of Thessaloniki   (Greece)

^aj UNIVERSITY OF PITTSBURGH   (United States)

^ak FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^al Hosp Univ V Rocío   (Spain)

^am Hosp Univ M Valdecilla IDIVAL   (Spain)

^an HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^ao UNIVERSITY OF ATHENS   (Greece)

^ap BASKENT UNIVERSITY   (Turkey)

^aq NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^ar UNIVERSITY OF CALGARY   (Canada)

^as HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^at Hospital Parc Tauli   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY RATE; MULTICENTER STUDY; PROPENSITY SCORE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; CLINICAL TRIAL; COMPARATIVE STUDY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; SECRETION (PROCESS); SEPSIS; SURVIVAL ANALYSIS;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84973303825     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv502     Document Type: Article

References (31)

1. Paterson DL, Bonomo R. Extended-spectrum b-lactamase: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
2. Pitout JDD, Laupland KB. Extended-spectrum b-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
3. Rodríguez-Baño J, Pascual A. Clinical significance of extended-spectrum b-lactamases. Expert Rev Anti Infect Ther 2008; 6: 671-83.
4. Vardakas KL, Tansarli GS, Rafailidis PI et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum b-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 2793-803.
5. Van Boeckel TP, Gandra S, Ashok A et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742-50.
6. Tzouvelekis LS, Markogiannakis A, Psichogiou M et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25: 682-707.
7. Zavascki AP, Carvalhaes CG, Picão RC et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010; 8: 71-93.
8. Nicolau DP, Carmeli Y, Crank CW et al. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents 2012; 39: 11-5.
9. Sousa D, Castelo-Corral L, Gutiérrez-Urbón JM et al. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology? J Antimicrob Chemother 2013; 68: 1917-25.
10. Hawser SP, Badal RE, Bouchillon SK et al. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intraabdominal infections: SMART 2002-2010. Int J Antimicrob Agents 2013; 41: 224-8.
11. Lee NY, Huang WH, Tsui KC et al. Carbapenem therapy for bacteremia due to extended-spectrum b-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011; 70: 150-3.
12. Collins VL, Marchaim D, Pogue JM et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrumb-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2012; 56: 2173-7.
13. Wu UI, Chen WC, Yang CS et al. Ertapenem in the treatment of bacteremia caused by extended-spectrum b-lactamase-producing Escherichia coli: a propensity score analysis. Int J Infect Dis 2012; 16: e47-52.
14. Lee NY, Lee CC, Huang WH et al. Carbapenem therapy for bacteremia due to extended-spectrum-b-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother 2012; 56: 2888-93.
15. Kiffer CR, Kuti JL, Eagye KJ et al. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Int J Antimicrob Agents 2006; 28: 340-4.
16. Burkhardt O, Kumar V, Schmidt S et al. Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. Int J Antimicrob Agents 2010; 35: 96-7.
17. Tängdén T, Adler M, Cars O et al. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBLproducing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. J Antimicrob Chemother 2013; 68: 1319-26.
18. von Elm E, Altman DG, Egger M et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.
19. Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
20. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-83.
21. McCabe WR, Jackson GG. Gram-negative bacteremia. Etiology and ecology. Arch Intern Med 1962; 110: 845-55.
22. Hilf M, Yu VH, Sharp J et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540-6.
23. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference. Crit Care Med 2003; 31: 1250-6.
24. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests-Eleventh Edition: Approved Standard M02-A11. CLSI, Wayne, PA, USA, 2012.
25. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716-23.
26. Speybroeck N. Classification and regression trees. Int J Public Health 2012; 57: 243-6.
27. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
28. Burkhardt O, Kumar V, Katterwe D et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007; 59: 277-84.
29. Dailly E, Arnould JF, Fraissinet F et al. Pharmacokinetics of ertapenem in burns patients. Int J Antimicrob Agents 2013; 42: 48-52.
30. Huang CC, Chen YS, Toh HS et al. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010. Int J Antimicrob Agents. 2012; 40 Suppl: S4-10.
31. Bettiol E, Rottier WC, Del Toro MD et al.; COMBACTE Consortium. Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies. Future Microbiol 2014; 9: 757-71.